We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
Read MoreHide Full Article
Jazz Pharmaceuticals plc (JAZZ - Free Report) announced that the marketing authorization application ("MAA") for its leukemia drug, Vyxeos received approval in Europe. The drug is approved for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adult patients.
The drug was approved in the United States for similar indications in August 2017. It generated sales of $54.2 million in the first six months of 2018. However, the company has lowered full-year revenue guidance for the drug as it performed below company’s expectations. The company will launch the drug country-by-country as and when pricing and reimbursement decisions are made. The impact of this approval on drug’s sales remains to be seen.
Jazz’s shares have returned 24.4% so far this year, outperforming the industry’s gain of mere 0.9%.
The MAA included data from five clinical studies, including a pivotal phase III study, which compared Vyxeos (cytarabine and daunorubicin liposome injection) to the current standard-of-care (7+3 chemotherapy regimen). The drug achieved a median overall survival of 9.6 months versus 5.9 months for standard of care. Vyxeos also achieved superiority in complete response rate.
Acute myeloid leukemia is progressive and a life-threatening blood cancer, which originates in bone marrow and spreads to other parts of the body through blood. Moreover, t-AML and AML-MRC have poor prognosis compared to other forms of leukemia and have limited treatment options available. Thus, there is significant unmet need in the targeted area.
Some better-ranked stocks from the same space are Endo International plc , BioSpecifics Technologies Corp and Pacira Pharmaceuticals, Inc. (PCRX - Free Report) . All the stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Endo’s earnings per share estimates have increased from $2.39 to $2.60 for 2018 and from $2.54 to $2.69 for 2019 over the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 29.11%. The stock has rallied 100.6% so far this year.
BioSpecifics’ earnings per share estimates have increased from $2.09 to $2.28 for 2018 and from $2.13 to $2.38 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 11.37%. The stock has rallied 19.5% so far this year.
Pacira’s earnings per share estimates have increased from 28 cents to 52 cents for 2018 and from $1.05 to $1.08 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 172.92%. The stock has increased 1.2% so far this year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
Jazz Pharmaceuticals plc (JAZZ - Free Report) announced that the marketing authorization application ("MAA") for its leukemia drug, Vyxeos received approval in Europe. The drug is approved for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adult patients.
The drug was approved in the United States for similar indications in August 2017. It generated sales of $54.2 million in the first six months of 2018. However, the company has lowered full-year revenue guidance for the drug as it performed below company’s expectations. The company will launch the drug country-by-country as and when pricing and reimbursement decisions are made. The impact of this approval on drug’s sales remains to be seen.
Jazz’s shares have returned 24.4% so far this year, outperforming the industry’s gain of mere 0.9%.
The MAA included data from five clinical studies, including a pivotal phase III study, which compared Vyxeos (cytarabine and daunorubicin liposome injection) to the current standard-of-care (7+3 chemotherapy regimen). The drug achieved a median overall survival of 9.6 months versus 5.9 months for standard of care. Vyxeos also achieved superiority in complete response rate.
Acute myeloid leukemia is progressive and a life-threatening blood cancer, which originates in bone marrow and spreads to other parts of the body through blood. Moreover, t-AML and AML-MRC have poor prognosis compared to other forms of leukemia and have limited treatment options available. Thus, there is significant unmet need in the targeted area.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC Price | Jazz Pharmaceuticals PLC Quote
Zacks Rank & Stocks to Consider
Jazz currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same space are Endo International plc , BioSpecifics Technologies Corp and Pacira Pharmaceuticals, Inc. (PCRX - Free Report) . All the stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Endo’s earnings per share estimates have increased from $2.39 to $2.60 for 2018 and from $2.54 to $2.69 for 2019 over the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 29.11%. The stock has rallied 100.6% so far this year.
BioSpecifics’ earnings per share estimates have increased from $2.09 to $2.28 for 2018 and from $2.13 to $2.38 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 11.37%. The stock has rallied 19.5% so far this year.
Pacira’s earnings per share estimates have increased from 28 cents to 52 cents for 2018 and from $1.05 to $1.08 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 172.92%. The stock has increased 1.2% so far this year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>